← board
KALV
KalVista Pharmaceuticals, Ltd.distress 1/10 · well-funded / low risk$27.000%today0% from 52w high
Lead: Hereditary Angioedema
Revenue
$41M
Liquidity
$214M
Runway
10.1 yrs
Shares 1y
+5%
Price & events
+63.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.2%
1W
+1.0%
1M
+55.4%
3M
+59.7%
6M
+106.3%
1Y
—
2Y
—
5Y
+204.7%
All
Overview
- Market Cap
- $1.44B
- Enterprise Value
- $1.40B
- Volume
- 0
- 52 Week Range
- $10.76 – $27.00
- Total Shares
- 53.24M
- Float Shares
- 38.18M
- Short %
- 14.37%
- % Held by Insiders
- 1.72%
- % Held by Institutions
- 136.88%
- Beta
- -0.11
Pipeline stages · 1 programs
KVD900 600 mg, KVD900 300 mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-05-27 | Phase 3 | KVD900 600 mg, KVD900 300 mg | Hereditary Angioedema | 145 | completed |
| 2026-05-27 | Phase 3 | KVD900 600 mg, Drug: KVD900 300 mg | Hereditary Angioedema | 11 | completed |
| 2026-01-15 | Phase 3 | KVD900 150 mg, KVD900 300 mg, KVD900 600 mg | Hereditary Angioedema | 36 | completed |
Catalyst news & presentations · 1
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (1)
- EKTERLYSEBETRALSTAT2025 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $27 (0% upside) · 3 analysts
- 2026-05-01HC Wainwright & Co.Buy → Neutral
- 2026-04-30NeedhamBuy → Hold
- 2026-03-26StifelBuy
- 2026-03-26CitizensMarket Outperform
- 2026-03-25NeedhamBuy
- 2026-01-09HC Wainwright & Co.Buy
Competitors — Hereditary Angioedema
Recent news
- 2026-07-19(KALV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
- 2026-07-16KALV Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued R&D Progress - Earnings Call Transcript - dars.gov.et
- 2026-07-13KalVista Pharmaceuticals (KALV) Holds Steady at $27.00: Key Support and Resistance Levels in Focus - Factor ETF Flow - dars.gov.et
- 2026-07-13KalVista Pharmaceuticals (KALV) Consolidates at $27.00 as Traders Eye Key Levels - Volatility Stop - DonanımHaber
- 2026-07-08(KALV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
- 2026-07-08KALV Q1 2026 Earnings: Narrower Loss Beats Expectations as Pipeline Progress Continues - Capex Guidance - dars.gov.et
- 2026-07-05KalVista Pharmaceuticals (KALV) Holds Steady at $27.00 Amid Key Technical Levels - Volatility Stop - dars.gov.et
- 2026-07-04KalVista Pharmaceuticals (KALV) Holds Steady at $27 as Traders Eye Key Levels - Bollinger Expansion - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.